The Quantellect read.As of Nov 19, 2026, 20 active firms cover Abbott Laboratories: 20 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $115.00 to $130.00, so the covering firms are broadly aligned. The average target of $121.68 sits 15% above the current $105.53. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 13% this year and 9% next, consensus EPS building from about $1.23 next quarter toward $5.94 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS20 active firms
Buy
Strong Buy00%
Buy20100%
Neutral00%
Sell00%
Strong Sell00%
Based on 20 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$121.68
+15.3% upside
Average target across 19 active firms as of Nov 19, 2026 vs $105.54 current
Highest Target$130.00
Average Target$121.68
Lowest Target$115.00
Detailed analyst forecasts for ABT
Showing 1–20 of 20 named analysts shown · 20 active firms in the rating projection
As of Nov 19, 2026, 20 of 20 active firms rate ABT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ABT EPS & revenue forecast
EPS · NEXT QUARTER
$1.23
Range $1.20 – $1.28 · 18 analysts · +7% YoY
Next period, 18 analysts expect Abbott Laboratories to earn $1.23 a share (range $1.20 – $1.28), versus $1.15 a year earlier. Full-year consensus is $5.52, growing to $5.94 the year after.
REVENUE · NEXT QUARTER
$12.6B
Range $12.4B – $12.7B · 18 analysts · +16% YoY
Revenue is expected to reach $12.6B (range $12.4B – $12.7B), +16.0% year-over-year. Full-year consensus is $49.9B, rising to $53.5B next year.
Top analysts covering Abbott Laboratories
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ABT.
#1
Joanne Wuensch
Citigroup · Rank #35
Buy
$122.00+15.6% to target
Overall win rate
51%
+ Follow
#2
Anthony Petrone
Mizuho · Rank #121
Neutral
$115.00+9.0% to target
Overall win rate
45%
+ Follow
#3
JB
Jayson Bedford
Raymond James · Rank #191
Buy
No targeton ABT
Overall win rate
44%
+ Follow
#4
Vijay Kumar
Evercore ISI Group · Rank #331
Buy
$120.00+13.7% to target
Overall win rate
36%
+ Follow
#5
Bruce Jackson
Benchmark · Rank #487
Buy
$120.00+13.7% to target
Overall win rate
36%
+ Follow
ABT stock forecast FAQ
What is ABT's average 12-month price target?+
The 19 active firms with a live target average $121.68 for Abbott Laboratories over the next 12 months, ranging from a $130.00 high to a $115.00 low, as of Nov 19, 2026.
Is ABT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 20 active firms as of Nov 19, 2026, 20 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ABT?+
The Street-high target is $130.00 (Wolfe Research), and the Street-low is $115.00 (Oppenheimer). The average of all 19 active-firm targets is $121.68.
How many active Wall Street firms cover ABT?+
20 active firms have a recognized rating on Abbott Laboratories as of Nov 19, 2026, and 19 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ABT?+
Among analysts who currently cover ABT, Joanne Wuensch of Citigroup has the strongest overall Quantellect track record (Rank #35). Their current call is Buy with a $122.00 target.
What is Abbott Laboratories's projected EPS for next quarter?+
The consensus estimate is $1.23 per share (range $1.20 – $1.28) across 18 analysts. Full-year EPS is projected at $5.52, rising to $5.94 the following year.
How much revenue is Abbott Laboratories expected to report next quarter?+
Consensus revenue is $12.6B (range $12.4B – $12.7B). Full-year revenue is projected at $49.9B, growing to $53.5B next year.
Have analysts been upgrading or downgrading ABT lately?+
As of Nov 19, 2026, 20 of 20 active firms rate ABT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ABT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.